Havrix Bambini (Hepatitis A Virus (Inactivated), Algeldrate)

Havrix Bambini is indicated for the prevention of hepatitis A infection in pediatric populations. The vaccine is used as part of routine immunization schedules to protect children from hepatitis A, a viral liver disease transmitted through contaminated food or water.

• Primary series of two doses administered at least six months apart.
• Booster dose may be recommended for continued protection in older children.
• Can be given to children aged 12 months and older according to national guidelines.
• Suitable for use in immunocompetent children without prior hepatitis A infection.
• May be co‑administered with other pediatric vaccines at separate injection sites.

Following vaccination, some recipients may experience mild to moderate reactions, while serious adverse events are rare. These reactions are generally self‑limiting and do not require specific treatment, although medical advice should be sought if they persist.

Common

• Pain, redness, or swelling at the injection site lasting up to a few days.
• Low‑grade fever (typically ≤38.5 °C) occurring within 24 hours.
• Mild headache or fatigue that resolves without treatment.
• Transient loss of appetite or mild gastrointestinal discomfort.
• Mild rash or itching at sites distant from the injection.
• Temporary joint discomfort or muscle aches.

Serious

• Allergic reactions such as urticaria, angioedema, or anaphylaxis requiring immediate medical attention.
• Neurological events like Guillain‑Barré syndrome, reported very rarely after vaccination.

Before administering Havrix Bambini, healthcare providers should assess the child’s medical history and current health status to ensure safe vaccination.

• Confirm no severe allergic reaction to any component, including algeldrate or previous hepatitis A vaccine.
• Defer vaccination in children with moderate or severe acute illness until recovery.
• Postpone if the child has a fever above 38 °C at the time of injection.
• Use caution in immunocompromised patients; vaccine may be less effective.
• Pregnancy considerations: vaccine is not routinely recommended for pregnant adolescents; consult obstetric guidance.
• Document any previous hepatitis A infection or documented immunity before vaccination.

Havrix Bambini does not have known pharmacokinetic interactions, but certain conditions or concurrent therapies may influence its safety or effectiveness.

Avoid

• Concurrent administration of live viral vaccines at the same anatomical site.
• Use in children with documented severe hypersensitivity to vaccine components.

Use with caution

• Concurrent immunosuppressive therapy may reduce antibody response.
• Administration with antipyretics may mask low‑grade fever post‑vaccination.
• Vaccination during acute febrile illness should be delayed.
• Consider timing of blood product transfusions, as they may interfere with immune response.